Form 8-K Summary
Registrant: Tivic Health Systems, Inc. The request metadata identifies Valion Bio, Inc., but the filing names Tivic Health Systems, Inc. as the registrant.
Reporting date: April 11, 2023. This is a Current Report under Section 13 or 15(d) of the Securities Exchange Act of 1934. The company is an emerging growth company, and its common stock trades on Nasdaq under the symbol TIVC.
Business Context
Under Item 7.01, the company furnished a press release announcing that it had filed its first patent relating to vagus nerve stimulation with the U.S. Patent Office. The press release was furnished as Exhibit 99.1 and is not deemed filed for purposes of Section 18 of the Exchange Act.
Financial and Operating Metrics
- The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, financial guidance, or other quantitative financial metrics.
- The filing does not provide details regarding the patent’s claims, filing number, jurisdictional status, development timeline, commercialization plans, or expected financial impact.
Material Changes and Outlook
The principal disclosed development is the filing of the company’s first vagus nerve stimulation patent. No comparable prior-period financial or operating information is provided, and the filing does not state whether the patent filing changes prior guidance or outlook.
Risks, Contingencies, and Unusual Items
The filing includes customary forward-looking statement disclaimers. It states that actual results may differ materially because of known and unknown risks, uncertainties, and other factors. Specific risks are referenced in the filing and other SEC documents, but are not detailed in the provided text.
The patent filing is not evidence that a patent has been granted. The filing text does not provide a clear value for any related costs, contingent obligations, or potential commercial benefits.
Investor Verification Checklist
- Verify the correct issuer: the filing is for Tivic Health Systems, Inc., not Valion Bio, Inc.
- Review Exhibit 99.1 for the patent’s scope, filing details, and management commentary.
- Confirm the patent’s prosecution and grant status with the U.S. Patent Office.
- Review subsequent SEC filings for development progress, commercialization plans, financing needs, and financial effects.
- Assess the forward-looking statements against the company’s broader risk disclosures and subsequent results.